[go: up one dir, main page]

Peng et al., 2022 - Google Patents

Dual-responsive disassembly of core-shell nanoparticles with self-supplied H2O2 and autocatalytic Fenton reaction for enhanced chemodynamic therapy

Peng et al., 2022

View HTML @Full View
Document ID
8673561384059588296
Author
Peng M
Ju E
Xu Y
Wang Y
Lv S
Shao D
Wang H
Tao Y
Zheng Y
Li M
Publication year
Publication venue
NPG Asia Materials

External Links

Snippet

Chemodynamic therapy holds great potential for cancer treatment due to its reliable curative effects, minimal invasiveness, and few systemic side effects. However, the limited amount of intracellular H2O2 makes achieving high-performance chemodynamic therapy challenging …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Peng et al. Dual-responsive disassembly of core-shell nanoparticles with self-supplied H2O2 and autocatalytic Fenton reaction for enhanced chemodynamic therapy
Wang et al. Self-assembled single-atom nanozyme for enhanced photodynamic therapy treatment of tumor
Zhou et al. Nanoscaled metal‐organic frameworks for biosensing, imaging, and cancer therapy
Zhang et al. An adenosine triphosphate-responsive autocatalytic Fenton nanoparticle for tumor ablation with self-supplied H2O2 and acceleration of Fe (III)/Fe (II) conversion
Zhao et al. Local generation of hydrogen for enhanced photothermal therapy
PN et al. Smart nanozymes for cancer therapy: the next frontier in oncology
Cheng et al. Biomimetic material degradation for synergistic enhanced therapy by regulating endogenous energy metabolism imaging under hypothermia
Bao et al. Bacterial template synthesis of multifunctional nanospindles for glutathione detection and enhanced cancer-specific chemo-chemodynamic therapy
Fan et al. In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy
Li et al. Photo‐Fenton‐like metal–protein self‐assemblies as multifunctional tumor theranostic agent
Huo et al. Tumor-selective catalytic nanomedicine by nanocatalyst delivery
Some et al. Cancer therapy using ultrahigh hydrophobic drug-loaded graphene derivatives
Zhang et al. Emerging integrated nanoclay-facilitated drug delivery system for papillary thyroid cancer therapy
Zeng et al. Vanadium oxide nanozymes with multiple enzyme-mimic activities for tumor catalytic therapy
Wang et al. Receptor-mediated and tumor-microenvironment combination-responsive Ru nanoaggregates for enhanced cancer phototheranostics
Yu et al. New insights into the synthesis, toxicity and applications of gold nanoparticles in CT imaging and treatment of cancer
Cheng et al. Supramolecular Tropism Driven Aggregation of Nanoparticles In Situ for Tumor‐Specific Bioimaging and Photothermal Therapy
Zelepukin et al. Flash drug release from nanoparticles accumulated in the targeted blood vessels facilitates the tumour treatment
Huo et al. Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron
Yang et al. Structural and molecular fusion MRI nanoprobe for differential diagnosis of malignant tumors and follow-up chemodynamic therapy
Zhang et al. PDGFB targeting biodegradable FePt alloy assembly for MRI guided starvation-enhancing chemodynamic therapy of cancer
Chen et al. Synergistic chemo-photothermal and ferroptosis therapy of polydopamine nanoparticles for esophageal cancer
Ou et al. Advancements in the Application of the Fenton Reaction in the Cancer Microenvironment
Carrese et al. Nanoparticles design for theranostic approach in cancer disease
Zou et al. Biomineralization-inspired synthesis of cerium-doped carbonaceous nanoparticles for highly hydroxyl radical scavenging activity